Effect of Emergency Department Bedside Compression Ultrasonography on Door-to-Disposition Time in Patients Suspicious for Lower Extremity Deep Venous Thrombosis

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05682040

Enrollment

Registered

2023-01-12

Start date

2017-04-01

Completion date

2018-06-01

Last updated

2026-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lower Extremity Deep Vein Thrombosis

Brief summary

Comparing the disposition time of point of care ultrasound (POCUS) versus formal lower extremity doppler in emergency department patients.

Interventions

DIAGNOSTIC_TESTBedside Compression Ultrasonography

Point of Care Ultrasound (Bedside Compression Ultrasonography) vs formal lower extremity Doppler

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Emergency Department patients presenting for lower extremity swelling concerning Deep vein thrombosis. \-

Exclusion criteria

Previous DVT or currently on anticoagulation \-

Design outcomes

Primary

Measure	Time frame	Description
Time to Completion of Point of Care Ultrasound in Emergency Room and Lower Extremity Doppler Prior to Disposition	Emergency Department admission to Disposition from Emergency Department	Completion time in minutes for point of care ultrasound (POCUS) in the emergency department followed by formal lower extremity (LE) doppler in radiology department prior to patient disposition from emergency department.

Secondary

Measure	Time frame	Description
Accuracy of POCUS vs Formal Lower Extremity Doppler	Upon completion of POCUS and formal lower extremity doppler until disposition from Emergency Department	The accuracy of POCUS vs formal doppler in making the diagnosis of lower extremity deep vein thrombosis in the number of participants who completed the study.

Countries

United States

Baseline characteristics

Characteristic	—
Age, Continuous	59 years
Region of Enrollment United States	56 Participants
Sex: Female, Male Female	34 Participants
Sex: Female, Male Male	22 Participants

Adverse events

Event type	EG000 affected / at risk
deaths Total, all-cause mortality	0 / 56
other Total, other adverse events	0 / 56
serious Total, serious adverse events	0 / 56

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 31, 2026